AAAAAA

   
Results: 1-13 |
Results: 13
Pharmacokinetics of the new antiepileptic drugs
Authors: Gidal, BE
Citation: Be. Gidal, Pharmacokinetics of the new antiepileptic drugs, AM J M CARE, 7(7), 2001, pp. S215-S220
Use of gabapentin in the treatment of neuropathic pain
Authors: Laird, MA Gidal, BE
Citation: Ma. Laird et Be. Gidal, Use of gabapentin in the treatment of neuropathic pain, ANN PHARMAC, 34(6), 2000, pp. 802-807
Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: a retrospective evaluation
Authors: Gidal, BE Walker, JK Lott, RS Shaw, R Speth, J Marty, KJ Rutecki, P
Citation: Be. Gidal et al., Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: a retrospective evaluation, SEIZURE-E J, 9(2), 2000, pp. 131-136
Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy
Authors: Gidal, BE Anderson, GD Rutecki, PR Shaw, R Lanning, A
Citation: Be. Gidal et al., Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy, EPILEPSY R, 42(1), 2000, pp. 23-31
Inter- and intra-subject variability in gabapentin absorption and absolutebioavailability
Authors: Gidal, BE Radulovic, LL Kruger, S Rutecki, P Pitterle, M Brockbrader, HN
Citation: Be. Gidal et al., Inter- and intra-subject variability in gabapentin absorption and absolutebioavailability, EPILEPSY R, 40(2-3), 2000, pp. 123-127
Intravenous valproic acid for myoclonic status epilepticus
Authors: Sheth, RD Gidal, BE
Citation: Rd. Sheth et Be. Gidal, Intravenous valproic acid for myoclonic status epilepticus, NEUROLOGY, 54(5), 2000, pp. 1201-1201
Antiepileptic drug interactions
Authors: French, JA Gidal, BE
Citation: Ja. French et Be. Gidal, Antiepileptic drug interactions, EPILEPSIA, 41, 2000, pp. S30-S36
Vigabatrin: A novel therapy for seizure disorders
Authors: Gidal, BE Privitera, MD Sheth, RD Gilman, JT
Citation: Be. Gidal et al., Vigabatrin: A novel therapy for seizure disorders, ANN PHARMAC, 33(12), 1999, pp. 1277-1286
Potential underreporting of intravenous phenytoin adverse events
Authors: Collins, M Gidal, BE Garnett, WRR Reinfeldt, G Tusch, GM
Citation: M. Collins et al., Potential underreporting of intravenous phenytoin adverse events, ANN PHARMAC, 33(1), 1999, pp. 111-112
The ketogenic diet
Authors: Bainbridge, JL Gidal, BE Ryan, M
Citation: Jl. Bainbridge et al., The ketogenic diet, PHARMACOTHE, 19(6), 1999, pp. 782-786
Therapeutic monitoring of topiramate: Evaluation of the saturable distribution between erythrocytes and plasma of whole blood using an optimized high-pressure liquid chromatography method
Authors: Gidal, BE Lensmeyer, GL
Citation: Be. Gidal et Gl. Lensmeyer, Therapeutic monitoring of topiramate: Evaluation of the saturable distribution between erythrocytes and plasma of whole blood using an optimized high-pressure liquid chromatography method, THER DRUG M, 21(5), 1999, pp. 567-576
Guidelines for nonemergency use of parenteral phenytoin products - Proceedings of an expert panel consensus process
Authors: Meek, PD Davis, SN Collins, M Gidal, BE Rutecki, PA Burstein, AH Fischer, JH Leppik, IE Ramsay, RE
Citation: Pd. Meek et al., Guidelines for nonemergency use of parenteral phenytoin products - Proceedings of an expert panel consensus process, ARCH IN MED, 159(22), 1999, pp. 2639-2644
Refractory status epilepticus: Response to ketamine
Authors: Sheth, RD Gidal, BE
Citation: Rd. Sheth et Be. Gidal, Refractory status epilepticus: Response to ketamine, NEUROLOGY, 51(6), 1998, pp. 1765-1766
Risultati: 1-13 |